ABC | Volume 113, Nº2, Agosto 2019

Artigo de Revisão Lamounier Júnior et al. Genética e miocardiopatia dilatada Arq Bras Cardiol. 2019; 113(2):274-281 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 20. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V, et al. Truncating FLNC Mutations Are Associated With High- Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol. 2016;68(22):2440-51. 21. Domínguez F, Cuenca S, Bili ń ska Z, Toro R, Villard E, Barriales-Villa R, et al. European Genetic Cardiomyopathies Initiative Investigators. Dilated Cardiomyopathy Due to BLC2-AssociatedAthanogene 3 (BAG3) Mutations. J Am Coll Cardiol. 2018;72(20):2471-81. 22. TayalU,PrasadS,CookSA.Geneticsandgenomicsofdilatedcardiomyopathy and systolic heart failure. Genome Med. 2017;9(1):20. 23. McNally EM, Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. Circ Res. 2017;121(7):731-48. 24. Ware JS, Cook SA. Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nat Rev Cardiol. 2018;15(4):241-52. 25. Peña-Peña ML, Monserrat L. Papel de la genética en la estratificación del riesgo de pacientes con miocardiopatía dilatada no isquémica. Rev Esp Cardiol. 2019;72(4):277-362. 26. Seidelmann SB, Laur O, Hwa J, Depasquale E, Bellumkonda L, Sugeng L, et al. Familial dilated cardiomyopathy diagnosis is commonly overlooked at the time of transplant listing. J Heart Lung Transplant. 2016;35(4):474-80. 27. Franaszczyk M, Chmielewski P, Truszkowska G, Stawinski P, Michalak E, Rydzanicz M, et al. Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations. PLoSOne. 2017;12(1):e0169007. 28. Roberts AM, Ware JS, Herman DS, Schafer S, Baksi J, Bick AG, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015;7(270):270ra6. 29. Cicerchia MN, Pena Pena ML, Salazar Mendiguchia J, Ochoa J, Lamounier Jr A, Trujillo JP. Prognostic implications of pathogenic truncating variants in the TTN gene. Eur Heart J. 2018;39(Suppl 1):875. 30. TayalU,NewsomeS,BuchanR,WhiffinN,WalshR,BartonPJ,etal.Truncating variants in titin independently predicts early arrhythmias in patients with dilated cardiomyopathy. J AmColl Cardiol. 2017;69(19):2466–8. 31. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared Genetic Predisposition in PeripartumandDilatedCardiomyopathies. NEngl J Med. 2016;374(3):233-41. 32. LinschotenM, TeskeAJ,Baas AF, Vink A,DooijesD, Baars HF, et al.Truncating Titin (TTN) Variants in Chemotherapy-InducedCardiomyopathy. J Card Fail. 2017;23(6):476-9. 33. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar- Mendiguchía J, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018;71(20):2293-302. 34. Captur G, Arbustini E, Bonne G, Syrris P, Mills K, Wahbi K, et al. Lamin and the heart. Heart. 2018;104(6):468-79. 35. Peretto G, Sala S, Benedetti S, Di Resta C, Gigli L, Ferrari M, Della Bella P. Updated clinical overview on cardiac laminopathies: an electrical and mechanical disease. Nucleus. 2018;9(1):380-91. 36. Ito M, Nomura S. Cardiomyopathy with LMNA Mutation. International Int Heart J. 2018;59(3):462-4. 37. Hasselberg NE, Haland TF, Saberniak J, Brekke PH, Berge KE, Leren TP, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J. 2018;39(10):853-60. 38. Priori SG, Blomström-Lundqvist C, Mazzanti A, BlomN, BorggrefeM, Camm J, et al. 2015 ESCGuidelines for themanagement of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for theManagementofPatientswithVentricularArrhythmiasandthePrevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric andCongenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867. 39. Charron P, Arbustini E, Bonne G. What Should the Cardiologist know about Lamin Disease? Arrhythm Electrophysiol Rev. 2012;1(1):22-8. 40. Captur G, Arbustini E, Syrris P, Radenkovic D, O’Brien B, MckennaWJ, et al. Lamin mutation location predicts cardiac phenotype severity: combined analysis of the published literature. Open Heart. 2018;5(2):e000915. 41. Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer DB, et al. Genotype-phenotypeassociations indilatedcardiomyopathy:meta-analysis on more than 8000 individuals. Clin Res Cardiol. 2017;106(2):127-39. 42. Begay RL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB, et al. Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell-Cell Adhesion Structures. JACC Clin Electrophysiol. 2018;4(4):504-14. 43. Norton N, Li D, Rieder MJ, Siegfried JD, Rampersaud E, Züchner S et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J HumGenet. 2011;88(3):273-82. 44. Reinstein E, Gutierrez-Fernandez A, Tzur S, Bormans C, Marcu S, Tayeb- Fligelman E et al. Congenital dilated cardiomyopathy caused by biallelic mutations in Filamin C. Eur J HumGenet. 2016;24(12):1792-6. 45. Chami N, Tadros R, Lemarbre F, Lo KS, BeaudoinM, Robb L, et al. Non sense mutations in BAG3 are associatedwith early-onset dilated cardiomyopathy in French Canadians. Can J Cardiol. 2014;30(12):1655-61. 46. Toro R, Pérez-Serra A, CampuzanoO, Moncayo-Arlandi J, Allegue C, Iglesias A, et al. Familial Dilated Cardiomyopathy Caused by a Novel Frameshift in the BAG3 Gene. PLoSOne. 2016;11(7):e0158730. 47. RafiqMA, Chaudhry A, CareM, Spears DA, Morel CF, Hamilton RM.Whole exome sequencing identified 1 base pair novel deletion in BCL2-associated athanogene 3 (BAG3) gene associated with severe dilated cardiomyopathy (DCM) requiring heart transplant in multiple family members. Am J Med Genet A. 2017;173(3):699-705. 48. Hermida-PrietoM,MonserratL,Castro-BeirasA,LaredoR,SolerR,PeteiroJet al.Familialdilatedcardiomyopathyandisolatedleftventricularnoncompaction associatedwith lamin A/C genemutations. Am J Cardiol. 2004;94(1):50-4. 49. Sedaghat-Hamedani F, Haas J, Zhu F, Geier C, Kayvanpour E, Liss M, et al. Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. Eur Heart J. 2017;38(46):3449-60. 50. López-Ayala JM, Gómez-Milanés I, Sánchez Muñoz JJ, Ruiz-Espejo F, Ortíz M, González-Carrillo J, et al. Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. Europace. 2014;16(12):1838-46. 51. GroenewegJA,vanderZwaagPA,JongbloedJD,CoxMG,VreekerA,deBoerRA, etal.Left-dominantarrhythmogeniccardiomyopathyinalargefamily:associated desmosomalornondesmosomalgenotype?HeartRhythm.2013;10(4):548-59. 52. Garcia-Pavia P, Syrris P, Salas C, Evans A, Mirelis JG, Cobo-Marcos M, et al. Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinic pathological study. Heart. 2011;97(21):1744-52. 53. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45(7):969-81. 54. Girolami F, Frisso G, Benelli M, Crotti L, Iascone M, Mango R, et al. Contemporarygenetictesting in inheritedcardiacdisease:tools,ethical issues, and clinical applications. T cardiovasc Med(Hagerstown). 2018;19(1):1-11 55. Van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, BonneG, Yaou RB,et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations :portend a high risk of sudden death¿ J Mol Med (Berl). 2005;83(1):79-83. 281